Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b proof-of-concept clinical trial of YTX-7739 exploring multiple ascending doses in adult healthy volunteers and patients with Parkinson's Disease

Trial Profile

A Phase 1b proof-of-concept clinical trial of YTX-7739 exploring multiple ascending doses in adult healthy volunteers and patients with Parkinson's Disease

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs YTX 7739 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept
  • Sponsors Kineta; Yumanity Therapeutics

Most Recent Events

  • 19 Dec 2022 According to a Kineta media release, Yumanity Therapeutics was merged with Kineta to form Kineta.
  • 12 Aug 2021 According to a Yumanity Therapeutics media release, topline results from the Phase 1b part of the MAD study is expected in the fall of 2021.
  • 22 Apr 2021 According to an Yumanity Therapeutics Media release, topline results from this study are expected in mid-2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top